[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischaemic-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischaemic-stroke":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,50,82,98,136,167,194,221,249],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053556","cognitive-care-bundle-for-ischaemic-stroke--a-pilot-randomised-controlled-trial-100053556",false,"NCT07610291","Cognitive Care Bundle for Ischaemic Stroke : A Pilot Randomised Controlled Trial","Application of Cognitive Care Bundle to Ischaemic Stroke Patients and Its Effect on Post-Stroke Cognitive Outcome: A Pilot Randomised Controlled Trial","COGIS","Inclusion Criteria:\n\n1. Age 18 years old or older\n2. Diagnosis of ischemic stroke within 7 days\n3. Mild cognitive impairment noted during admission of stroke (MoCA 18-25)\n\nExclusion Criteria:\n\n1. GCS \\\u003C8\n2. Pre-stroke neurodegenerative disease (Parkinson's, Alzheimer's, Vascular Dementia, Frontotemporal Dementia, Mixed Dementia, Lewy Body Dementia)\n3. Patient with previous stroke\n4. Modified Rankin Scale of 4 and above\n5. Known psychiatric disorder\n6. Patient on psychotherapy medications (benzodiazepine, antidepressant, etc)\n7. Severe aphasia\n8. Logistical issues hindering follow up\n9. Delirium","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if a set of treatments, called a \"cognitive care bundle,\" can help preserve cognitive ability in people who have had a stroke. This study will also test how feasible it is for people to follow this care bundle.\n\nThe main questions it aims to answer are:\n\n1. Do people find it feasible to follow the care bundle, which includes daily home blood pressure checks (and blood sugar checks for those with diabetes), along with referrals to specialists like dietitians, eye doctors, hearing specialists, and mental health professionals?\n2. Do people who receive the cognitive care bundle have better cognitive scores 3 months after their stroke, compared to those who receive standard care?\n\nResearchers will compare two groups of stroke survivors. One group will receive the cognitive care bundle plus standard medical care. The other group will receive standard medical care alone. This comparison will help researchers see if the care bundle works better to prevent cognitive decline.\n\nParticipants in the intervention (care bundle) group will:\n\nCheck and record their blood pressure daily at home (and their blood sugar too, if they have diabetes). Talk with a doctor weekly over the phone to review their readings and adjust medications if needed\n\nSee a dietitian for a personalized eating plan\n\nHave a hearing test by an audiologist\n\nHave a basic vision test by the research team\n\nAnswer a short questionnaire about their mood to screen for depression\n\nAll participants (in both groups) will undergo physiotherapy and cognitive training. Participants will be followed up with blood tests, examination by a doctor and questionnaires after 3 months.\n\nThis is a pilot study to see if this approach works and is practical to do in a larger future study.",[27,28],"Ischaemic Stroke","Cognitive Impairment, Mild",[30,31,32,33,34,35,36],"post-stroke cognitive impairment","care bundle","pilot","intervention","cognitive rehabilitation","blood pressure","hyperglycaemia","NOT_YET_RECRUITING","2026-07-10",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":21},"2026-06",{"date":45,"type":21},"2029-04",{"name":47,"class":48},"National University of Malaysia","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100633461","phase-3-efficacy-and-safety-of-minocycline-in-patients-with-acute-ischaemic-stroke-receiving-intravenous-thrombolysis-100633461","NCT07526987","Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis","Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis (EMPHASIS-2): A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Trial","EMPHASIS-2","Inclusion Criteria:\n\n1. Age between 18 and 80 years;\n2. Patients with acute ischaemic stroke confirmed by CT or MRI;\n3. Having received or planning to receive intravenous thrombolysis within 4.5 hours of onset or within an extended window of 4.5-24 hours based on guideline recommendations (The intravenous thrombolytic drugs include: alteplase, tenecteplase, reteplase or recombinant human prourokinase);\n4. The study drug can be applied before intravenous thrombolysis or within 2 hours after the initiation of intravenous thrombolysis;\n5. 6≤NIHSS≤25, and Ia≤1;\n6. Signed informed consent.\n\nExclusion Criteria:\n\n1. mRS score ≥ 2 prior to onset of the current stroke;\n2. History of pseudomembranous colitis or antibiotic-associated colitis;\n3. Known allergy or intolerance to tetracycline antibiotics or any component of minocycline;\n4. Known resistance to other tetracyclines;\n5. Use of tetracycline antibiotics within the past 7 days;\n6. Presence of a known community-acquired bacterial infection (e.g., pneumonia, urinary tract infection) or any other concurrent infection requiring antibiotic treatment;\n7. History of intracranial hemorrhagic disease within the past 3 months, for example, parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural or epidural hematoma.\n8. Malformation, tumor, abscess, or other major non-ischaemic brain diseases (e.g., multiple sclerosis, other intracranial space-occupying lesions) on baseline cranial CT or MRI;\n9. Rare or unknown etiology of large vessel occlusion (e.g., arterial dissection, vasculitis);\n10. History of systemic lupus erythematosus;\n11. Known severe hepatic insufficiency (ALT or AST \\> 3 times of the upper limit of normal), severe renal insufficiency (creatinine \\> 3.0 mg\u002FdL \\[265.2 μmol\u002FL\\], estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73m², or have received dialysis before randomization);\n12. Use of tretinoin, androgen or antiandrogen treatment (e.g., anabolic steroids, spironolactone) within the past 3 months;\n13. Pregnant, breastfeeding, or of childbearing potential who are unwilling to use effective contraception throughout the study;\n14. Presence of a severe non-cardio-cerebrovascular disease with a life expectancy of less than 6 months;\n15. Participation in any other clinical trial within the past 30 days;\n16. Any other condition that is not suitable for participating in this clinical trial, such as inability to understand or follow the study procedures due to physical, cognitive, emotional, or mental disorders.","80 Years",{"count":60,"type":21},934,[62],"PHASE3","The aim of this study is to assess the efficacy and safety of minocycline in improving functional outcome among patients with acute ischaemic stroke receiving intravenous thrombolysis.",[27],[66,67,68,69,70],"Ischaemic stroke","Intravenous thrombolysis","Minocycline","Randomized Controlled Trial","Functional outcome","RECRUITING","2026-06-30",{"date":74,"type":41},"2026-07-01",{"date":76,"type":41},"2026-06-05",{"date":78,"type":21},"2028-12-31",{"name":80,"class":48},"Beijing Tiantan Hospital",3,{"id":83,"slug":4,"hasResults":11,"nctId":12,"briefTitle":84,"officialTitle":85,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":25,"conditions":88,"keywords":90,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":97,"locationsCount":49},"100640607","COGnitive Care Bundle for Ischaemic Stroke : a Pilot Randomised Controlled Trial","APPLICATION OF COGNITIVE CARE BUNDLE TO ISCHAEMIC STROKE PATIENTS AND ITS EFFECT ON POST-STROKE COGNITIVE OUTCOME: A PILOT RANDOMISED CONTROLLED TRIAL",{"count":20,"type":21},[24],[27,89],"Cognitive Impairments, Mild",[91],"post-stroke cognitive impairment, care bundle, pilot, intervention, cognitive rehab, blood pressure, hyperglycaemia","2026-05-20",{"date":94,"type":41},"2026-05-27",{"date":43,"type":21},{"date":45,"type":21},{"name":47,"class":48},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":119,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":49},"100633435","head-cooling-in-ischaemic-stroke-patients-undergoing-endovascular-thrombectomy-coolhead-2b-100633435","NCT07526649","Head Cooling in Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy (COOLHEAD-2b)","Head Cooling in Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy: A Phase 2 Randomised Controlled Trial (COOLHEAD-2b)","COOLHEAD-2B","Inclusion Criteria:\n\n* Acute anterior circulation ischaemic stroke planned for endovascular thrombectomy\n* Age ≥18 years\n\nExclusion Criteria:\n\n* Pre-stroke modified Rankin Scale score \\>2\n* Core body temperature \\\u003C35°C at admission\n* Uncontrolled hypertension (≥185\u002F110 mmHg despite treatment in IVT-eligible patients)\n* Known contraindications to hypothermia (e.g., haemodynamic instability, symptomatic bradyarrhythmia, cryoglobulinaemia, sickle cell disease, cold agglutinins)\n* Vasospastic disorders (e.g., Raynaud's phenomenon)\n* Skin lesions preventing secure application of the cooling cap\n* Inability to participate in 90-day follow-up",{"count":107,"type":21},182,[24],"COOLHEAD-2b is a multicentre, phase 2, prospective, randomised, controlled, open-label, blinded-endpoint trial evaluating the safety and efficacy of non-invasive convective head cooling as an adjunct to endovascular thrombectomy (EVT) in patients with acute anterior circulation ischaemic stroke. Head cooling is initiated as early as possible, including during inter-hospital transfer, and continued until one hour after reperfusion. The primary efficacy endpoint is final infarct volume at 24 hours.",[111,112,113,27,114,115,116,117,118],"Stroke","Acute Ischemic Stroke","Brain Ischemia","Thrombectomy","Endovascular Procedures","Reperfusion Injury","Cooling","Large Vessel Occlusion",[120,121,122,123,124,125],"Head cooling","Selective brain cooling","Endovascular thrombectomy","Therapeutic hypothermia","Penumbra","Neuroprotection","2026-04-09",{"date":128,"type":41},"2026-04-13",{"date":130,"type":21},"2026-04-10",{"date":132,"type":21},"2029-06-30",{"name":134,"class":135},"Auckland City Hospital","OTHER_GOV",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100632298","digital-application-for-stroke-health-100632298","NCT07511868","Digital Application for Stroke Health","Evaluating a Digital Health Application for Post-stroke Care and Vascular Risk Factor Management - a Multicenter Randomized Controlled Clinical Investigation","DASH","Inclusion Criteria:\n\n1. Male or female patient (biological sex) ≥18 years at the time of consent\n2. Hospitalization for acute ischemic stroke, acute haemorrhagic stroke or TIA\n3. Necessary Technical Equipment (smartphone or tablet computer) and skills\n4. Able to provide informed consent\n\nExclusion Criteria:\n\n1. Cerebral infarction due to cerebral venous thrombosis (CVT)\n2. Severe Psychiatric Conditions\n3. Severe pre-existing cognitive impairment\n4. Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) or other patients where salt restriction is harmful.\n5. Inability to operate the device independently (assistance from a caregiver is acceptable). E.g.:\n\n   * Severe apraxia,\n   * Severe Motor Disabilities,\n   * Severe Visual Impairment\n   * Severe Communication Barriers (e.g. Severe Aphasia, Severe Dysarthria)\n6. Inability to speak and read German to a level which allows fully comprehending the meaning of everything that is said and written.\n7. Women of childbearing potential not willing to adopt effective contraceptive measures during the clinical investigation\n8. Patients who are considered to be part of the vulnerable population:\n\n   * Persons unable to give consent\n   * Minors\n   * Persons performing military service\n   * persons detained by court or official order or accommodated in accordance with the Accommodation Act, Federal Law Gazette No. 155\u002F1990\n   * Pregnant or breastfeeding women",{"count":145,"type":21},500,[24],"Stroke is a leading cause of death and long-term disability worldwide. Despite substantial advances in acute stroke care, there remains a lack of evidence-based digital solutions to support patients after hospital discharge. This study evaluates the effectiveness of a digital health application (StrokeApp) designed to support patients with ischemic or hemorrhagic stroke or transient ischemic attack (TIA) in secondary prevention and recovery.\n\nIn this multicenter, randomized, controlled, open-label trial, 500 patients will be assigned in a 1:1 ratio to receive either standard care alone or standard care in combination with StrokeApp. The primary objective is to assess the impact of the application on health-related quality of life three months after discharge. Secondary and exploratory outcomes include health literacy, medication adherence, vascular risk factors, health-related behaviors, psychosocial outcomes, long-term recovery up to twelve months, as well as safety and user experience.",[149,27,150],"Haemorrhagic Stroke","Transient Ischemic Attack (TIA)",[152,153,154,155,156],"Digital Health Application","Post Stroke","Medical Device","App","stroke aftercare","2026-03-30",{"date":159,"type":41},"2026-04-06",{"date":161,"type":21},"2026-04-01",{"date":163,"type":21},"2026-12-31",{"name":165,"class":48},"VASCage GmbH",7,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":193},"100591993","phase-2-a-clinical-study-to-investigate-the-effect-of-oral-neflamapimod-on-motor-recovery-after-acute-ischaemic-stroke-100591993","NCT06987643","A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke","A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke","RESTORE","Inclusion Criteria:\n\n* Male or female participants must be aged 45 years or over at the time of signing the informed consent.\n* Confirmed acute ischaemic stroke in the anterior circulation (middle or anterior cerebral artery) with onset of symptoms between 2 and 7 days prior to screening and evaluation.\n* National Institutes of Health Stroke Scale (NIHSS) score between 5 and 20 (inclusive) and exhibiting unilateral motor deficit (i.e. motor NIHSS ≥ 2 on affected side of the body).\n* Fugl-Meyer Assessment of Motor Recovery after Ischaemic Stroke (FMMS) total motor components score of 80 or below.\n* No history of learning difficulties that may interfere with their ability to complete the cognitive tests.\n\nExclusion Criteria:\n\n* Evidence of progressive or unstable stroke or intra-cerebral haemorrhage in the opinion of the investigator\n* Participants needing carotid surgery within 3 months\n* Ongoing major and active psychiatric disorder and\u002For other concurrent medical condition that, in the opinion of the Investigator, might compromise safety and\u002For compliance with study requirements.\n* History of alcohol or drug abuse within the previous 2 years.\n* Poorly controlled clinically significant medical illness, such as hypertension (blood pressure \\>180 mmHg systolic or 100 mmHg diastolic); myocardial infarction within 6 months; uncompensated congestive heart failure or other significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic\u002Fendocrine disorders or other disease that would interfere with assessment of drug safety in the opinion of the Investigator.\n* Abnormal laboratory tests that, in the Investigator's assessment, mean that a participant is not appropriate for participation in this study, including, but not limited to:\n\n  1. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>2.0\n\n     × the upper limit of normal (ULN),\n  2. Total bilirubin \\>1.5 × ULN, and\u002For\n  3. International Normalised Ratio (INR) \\>1.5 NOTE: Participants with Gilbert's syndrome can be included with total bilirubin \\>1.5 x ULN as long as direct bilirubin is ≤ 1.5 x ULN)","45 Years",{"count":177,"type":21},90,[179],"PHASE2","The purpose of this interventional study is to determine whether neflamapimod can improve residual physical disability and\u002For cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke.",[182,27],"Moderate to Severe Acute Ischaemic Stroke","2026-02-05",{"date":185,"type":41},"2026-02-09",{"date":187,"type":41},"2025-06-20",{"date":189,"type":21},"2026-06-28",{"name":191,"class":192},"EIP Pharma Inc","INDUSTRY",12,{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":204,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":220,"locationsCount":49},"100588379","exploratory-study-on-the-potential-cross-system-effects-of-bci-fes-hand-therapy-on-dysphagia-and-aphasia-in-chronic-stroke-patients-100588379","NCT06940635","Exploratory Study on the Potential Cross-System Effects of BCI-FES Hand Therapy on Dysphagia and Aphasia in Chronic Stroke Patients","Cross-Stroke Therapy Effects With BCI and FES Stimulation: A Pilot Study","c-STEPS","Inclusion Criteria:\n\n* Age: Participants must be aged 18 years or older.\n* Post-Stroke Phase: Participants must be within the chronic post-stroke phase (time since ischemic or haemorrhagic stroke greater than 3 months).\n* Motor Impairment: Participants must exhibit disabling left or right residual arm paresis (\"left\u002Fright arm motor drift\" part of the NIHSS score ≥1).\n* Speech\u002FSwallowing Impairment: Participants must have:\n\n  * Aphasia (AAT-Skala zum Kommunikationsverhalten score ≤3), and\u002For\n  * Dysphagia (MUCCS-N score ≥2).\n* Stable Neurological Status: No relevant changes in neurological status in the past 4 weeks (self-reported).\n* Motor Function: Participants must be able to raise at least 1 block similar to the ones in Box-and-Block-Test.\n* Cognitive Understanding: Participants must be able to understand basic spoken instructions.\n* Sitting Tolerance: Participants must be able to maintain a sitting position for at least 60 minutes.\n* Willingness to Participate: Participants must be willing to participate in the study and able to understand and sign the informed consent.\n\nExclusion Criteria:\n\n* Cognitive Impairments: Cognitive impairments that, in the investigator's judgment, could limit understanding of task instructions.\n* Stroke Location: Participants with a brainstem and\u002For cerebellar stroke.\n* Previous Stroke: Participants with a previous disabling stroke.\n* Hemi-Neglect: Pronounced hemi-neglect at the last documented therapy visit that limits compliance with treatment intervention (investigator's judgment).\n* Anosognosia: Pronounced anosognosia at the last documented therapy visit that limits compliance with treatment intervention (investigator's judgment).\n* Spasticity: Severe spasticity in the affected limb, resulting in complete rigidity in flexion or extension.\n* Seizure Disorders: Participants with uncontrolled epilepsy (investigator's judgement) or epileptic seizure within the last month.\n* Intracranial Pressure: Known ongoing elevated intracranial pressure.\n* Implanted Medical Devices: Participants with implanted medical devices with contraindication for FES such as pacemakers.\n* Metallic Fragments: Participants with implanted metallic fragments in the extremity planned for FES that would limit the use of functional electrical stimulation (FES).\n* Unhealed Injuries: Unrecovered fractures or skin\u002Ftissue lesions in the FES stimulated extremity.\n* Joint Issues: Ossification, contraction, or stiffness of the wrist joint in the FES stimulated extremity that would limit treatment.\n* Botulinum Toxin: Participants who received botulinum-toxin treatment within 6 weeks prior to study inclusion and\u002For for whom botulinum-toxin treatment is planned during the study duration.\n* Co-morbidities: The following conditions will exclude participation:\n\n  * Chronic Obstructive Pulmonary Disease (Stage IV).\n  * Cardiac insufficiency (NYHA Stage IV).\n  * Severe acute infections.\n  * Significant circulatory disturbances in the stimulated extremity.\n  * Sensory disorders that significantly impair the patient's ability to feel pain or react to unsuitable proprioceptive stimuli.\n  * Any other general medical conditions that, in the investigator's judgment, limit the safety or performance of study procedures (investigator's judgement).\n* Electrical Stimulation Intolerance: Known inability to tolerate cutaneous electrical stimulation.",{"count":203,"type":21},10,[24],"The goal of this neurorehabilitation explorative study is to investigate how a closed-loop Brain-Computer Interface Functional Electrical Stimulation (BCI-FES) therapy, used within the intended purpose for hand rehabilitation, may impact swallowing difficulties (dysphagia) and language disorders (aphasia) in post-stroke patients.",[27,207],"Hemorrhagic Stroke",[209,210,211,212,213],"neurorehabilitation","BCI-FES","chronic stroke","aphasia","dysphagia","2025-11-25",{"date":216,"type":41},"2025-11-26",{"date":218,"type":41},"2025-06-04",{"date":72,"type":21},{"name":165,"class":48},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":234,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":247,"locationsCount":49},"100608164","the-retrain-trial-phase-2-100608164","NCT07197996","The RETRAIN Trial Phase 2","MonitoRing the Effect of Intermittent Pneumatic Compression and TRAnscutaneous Functional electrIcal Stimulation of the Common Peroneal Nerve Using the Geko® Device on Cerebral Haemodynamics in Patients With Ischaemic Strokes (The RETRAIN Trial Phase 2)","RETRAIN 2","Inclusion Criteria:\n\n1. Adult over 18\n2. Patient with ischaemic stroke diagnosis confirmed by a stroke physician.\n3. Within 36 hours of symptom onset.\n4. Unable to stand or mobilise without assistance.\n5. No intracerebral haemorrhage as ruled out by computerised tomography (CT) or Magnetic Resonance Imaging (MRI) scan.\n\nExclusion Criteria:\n\n1. Inability to gain consent from the patient, or a declaration from a Personal Consultee or Nominated Consultee.\n2. Absence of a transient ischaemic attack (TIA).\n3. Clinically apparent deep vein thrombosis at screening\n4. Patient is expected to require palliative care within 14 days\n5. No response to the geko® device i.e. no involuntary rhythmic upward and outward movement of the foot (dorsiflexion) at the maximum tolerable device setting.\n6. Contraindications for the use of the geko™ device\n\n   * Allergy to hydrogel constituents\n7. Contraindications to IPC\n\n   * Severe peripheral vascular disease\n   * Large leg ulcers requiring extensive bandaging (small ulcers or skin breaks with flat coverings are not an exclusion)\n   * Severe oedema\n   * Leg deformities making appropriate fitting impossible\n   * Symptomatic congestive cardiac failure of NYHA class IV (symptoms of heart failure at rest, any physical activity causing further discomfort).\n8. Single or double leg amputations.\n9. Participation in any other clinical trial\n10. Patients must not have a current coronavirus (COVID-19) infection",{"count":230,"type":21},80,[24],"Ischaemic strokes, caused by a disruption in the brain's blood supply, are the second leading cause of death and disability in the United Kingdom. This single-center prospective randomised study aims to measure cerebral blood flow and oxygen delivery in patients who have recently suffered an ischaemic stroke and are using either the geko® neuromuscular electrostimulation device or an intermittent pneumatic compression (IPC) device as part of their routine clinical care.\n\nThe geko® device stimulates a nerve in the lower leg, inducing muscle contractions that enhance blood circulation. The IPC device applies controlled external pressure through compressed air and a pump, cyclically inflating and deflating chambers in a sleeve worn on the leg. This mimics the action of calf muscles to promote blood flow.\n\nThe primary objective of this study is to assess the effect of the geko® and IPC devices on cerebral blood flow in stroke patients, specifically during the hyperacute phase (within 36 hours) following an ischaemic stroke. Both devices will be used as part of standard care for VTE prevention. Cerebral blood flow will be measured using functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG).",[27],[235,236,237,238,239,240],"Acute ischemic stroke","Neuromuscular electrostimulation","Effects on cerebral blood flow","Randomised controlled trial","Cerebral blood flow measurements","Stroke rehabilitation","2025-09-25",{"date":243,"type":41},"2025-09-30",{"date":245,"type":41},"2025-07-01",{"date":74,"type":21},{"name":248,"class":192},"Firstkind Ltd",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":256,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":257,"targetDuration":259,"studyType":260,"phases":4,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":49},"100510138","a-cohort-study-of-ischemic-cerebrovascular-disease-100510138","NCT05922540","a Cohort Study of Ischemic Cerebrovascular Disease","a Prospective, Multicenter Cohort Study of Ischemic Cerebrovascular Disease","Inclusion Criteria:\n\n1. Clinical diagnosis of ischemic stroke.\n2. Age ≥ 18 years.\n3. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Patients with moderate to severe mental disorders or dementia who cannot cooperate to complete the informed consent and follow-up procedures.\n2. Patients with neurological functional impairment caused by conditions such as migraine aura, epilepsy, or other non-ischemic strokes.\n3. Agitated patients who cannot cooperate with imaging examinations.\n4. Pregnant or lactating patients, as well as those planning to become pregnant within 90 days.\n5. Patients with concurrent malignant tumors or severe systemic diseases with an expected survival period of less than 90 days.\n6. Patients who have participated in other clinical studies within 30 days prior to enrollment or are currently participating in other interventional clinical studies.",true,{"count":258,"type":21},5000,"3 Months","OBSERVATIONAL","This study aims to establish a multicenter, large-scale, prospective cohort of patients with ischemic stroke. Various biological samples such as blood, feces, and urine are collected to identify biomarkers associated with ischemic stroke. By integrating demographic information, clinical indicators, imaging parameters, and biomarker parameters, the study aims to develop risk assessment, early warning, and prognosis prediction models. Additionally, the study aims to identify key genes and explore relevant signaling pathways related to ischemic stroke.",[27],"2023-06-27",{"date":265,"type":41},"2023-06-28",{"date":267,"type":41},"2022-11-01",{"date":269,"type":21},"2027-11-01",{"name":271,"class":48},"Xiangya Hospital of Central South University"]